Aivalli Praveen Kumar, Elias Maya Annie, Pati Manoj Kumar, Bhanuprakash Srinath, Munegowda Chikkagollahalli, Shroff Zubin Cyrus, Srinivas Prashanth N
Institute of Public Health, Bangalore, Karnataka, India.
Alliance for Health Policy and Systems Research, World Health Organization, Geneva, Switzerland.
BMJ Glob Health. 2018 Jan 13;2(Suppl 3):e000644. doi: 10.1136/bmjgh-2017-000644. eCollection 2017.
Generic medicines are an important policy option to reduce out-of-pocket expenditure on medicines. However, negative perceptions of their quality affect utilisation and raise issues of confidence and trust in medicines and health services. The aim of the study was to test the quality of generic and branded medicines and explain negative perceptions towards generic medicines.
The study was part of a larger study on access to medicines. Information on various quality parameters was collected for branded medicines and branded and unbranded generic versions of the same medicines from government and private pharmacies in Karnataka in Southern India. To assess perceptions related to quality and drivers of preferred point of care (public vs private), focus group discussions were conducted with diabetes and hypertension patients, health workers and private pharmacists. The results of the quality tests were assessed and thematic analysis was conducted on the qualitative data to develop a conceptual framework to explain perceptions of medicine and care quality in the local health system.
The generic and branded variants of the medicines tested were of comparable quality. Contrary to the quality test results, patients' and health workers' perceptions of quality were largely in favour of branded medicines. Negative perceptions of medicine quality along with other drivers contribute towards choosing more expensive medicines in the private sector. Trust in the health system emerged as an underlying central theme that explained and drove choice of medicines and providers within the local health system.
Negative perceptions of generic medicines and preferential promotion of branded medicines over generics by pharmaceutical companies could influence prescriber behaviour and affect trust in healthcare provided in public services. To succeed, access to medicines programmes need to systematically invest in information on quality of medicines and develop strategies to build trust in healthcare offered in government health services.
仿制药是减少药品自付费用的一项重要政策选择。然而,对其质量的负面看法影响了其使用,并引发了对药品和医疗服务的信心和信任问题。本研究的目的是检测仿制药和品牌药的质量,并解释对仿制药的负面看法。
该研究是一项关于药品可及性的更大规模研究的一部分。从印度南部卡纳塔克邦的政府和私人药房收集了品牌药以及同一药品的品牌和非品牌仿制药版本的各种质量参数信息。为了评估与质量相关的看法以及首选医疗服务点(公立与私立)的驱动因素,对糖尿病和高血压患者、医护人员及私人药剂师进行了焦点小组讨论。对质量检测结果进行了评估,并对定性数据进行了主题分析,以建立一个概念框架来解释当地卫生系统中对药品和医疗质量的看法。
所检测药品的仿制药和品牌药变体质量相当。与质量检测结果相反,患者和医护人员对质量的看法在很大程度上偏向品牌药。对药品质量的负面看法以及其他驱动因素促使人们在私立部门选择更昂贵的药品。对卫生系统的信任成为一个潜在的核心主题,它解释并推动了当地卫生系统内药品和服务提供者的选择。
对仿制药的负面看法以及制药公司对品牌药相对于仿制药的优先推广可能会影响开处方者的行为,并影响对公共服务中提供的医疗保健的信任。为取得成功,药品可及性项目需要系统性地投资于药品质量信息,并制定策略以建立对政府卫生服务中提供的医疗保健的信任。